06:46 AM EDT, 09/22/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday the US Food and Drug Administration approved a subcutaneous induction regimen of Tremfya to treat moderately to severely active ulcerative colitis in adult patients.

Commercially insured patients may be eligible to receive their first induction treatment in as little as 24 hours through Tremfya withMe, the drugmaker said.

Ulcerative colitis is a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, that produce pus and mucus.